IPS Cell Therapy » Molecular Medicine

Study Identifies Molecular Mechanism Triggering Parkinson’s Disease

admin — Sat, 31 Jul 2010 08:16:10 +0000

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson’s disease. This discovery not only may explain how a genetic mutation linked to Parkinson’s causes the cells’ death, but could also open the door to new therapeutic approaches for the malady…

Stanford study identifies molecular mechanism triggering Parkinson’s Disease

admin — Thu, 29 Jul 2010 08:17:44 +0000

In a multi-step malfunction, a genetic mutation linked to Parkinson’s Disease causes impairment of molecules called microRNAs, ultimately causing death of critical brain cells.

Baylor College of Medicine Awarded $14.85 Million Grant to Complete Neurological Research Center at Texas Children’s …

admin — Thu, 29 Jul 2010 08:17:44 +0000

HOUSTON, July 28 /PRNewswire-USNewswire/ — Neurological research at Baylor College of Medicine (BCM) and Texas Children’s Hospital is getting a big boost in the form of a $14.85 million grant from the National Institutes of Health (NIH) to complete two floors of the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children’s Hospital. “More than 300 million children suffer from …

American Society for Biochemistry and Molecular Biology honors 11 outstanding scientists

admin — Thu, 29 Jul 2010 08:17:44 +0000

( American Society for Biochemistry and Molecular Biology ) The American Society for Biochemistry and Molecular Biology last week named 10 scientists the winners of the nonprofit’s annual awards. Another winner was announced earlier this year.

Molecular mechanism triggering Parkinson’s disease identified

admin — Thu, 29 Jul 2010 08:17:44 +0000

Molecular Mechanism Triggering Parkinson’s Disease Identified In Stanford Study

admin — Thu, 29 Jul 2010 08:17:44 +0000

Non-Human Sugar In Biotech Drugs Causes Inflammation

admin — Tue, 27 Jul 2010 08:16:35 +0000

Researchers at the University of California, San Diego School of Medicine have discovered that a kind of sugar molecule common to chimpanzees, gorillas and other mammals but not found in humans provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.This non-human sialic acid sugar is an ingredient in some biotechnology drugs …

Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine

admin — Tue, 27 Jul 2010 08:16:35 +0000

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning ZiplexÂ® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip.

Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine

admin — Tue, 27 Jul 2010 08:16:35 +0000

ANAHEIM, Calif. and TORONTO, July 26 /PRNewswire/ — Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American …

Halcyon Moleculars William Andregg: The Only Way To Reach The Stars Is To Live Longer

admin — Sun, 25 Jul 2010 08:16:22 +0000

This weeks episode of Speaking Of (video below) features the founder/CEO of Halcyon Molecular, William Andregg. Andregg grew up in Arizona. There’s a song by The Orb called Little Fluffy Clouds that describes the light-pollution-free Arizonan sky quite perfectly, with amazing clouds, sunsets and stars. Most Arizonans – at some point in their lives – will lay on the hood of their car and gaze …

Cytrxs tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

admin — Fri, 23 Jul 2010 08:17:07 +0000

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx’s oncology drug candidate tamibarotene.

Study Points to Molecular Origins of Celiac Disease

admin — Fri, 23 Jul 2010 08:17:07 +0000

Title: Study Points to Molecular Origins of Celiac Disease Category: Health News Created: 7/21/2010 2:10:00 PM Last Editorial Review: 7/22/2010

Study Points to Molecular Origins of Celiac Disease

admin — Thu, 22 Jul 2010 08:18:57 +0000

WEDNESDAY, July 21 (HealthDay News) — Scientists believe they’ve identified the molecular triggers of celiac disease, a finding they say could lead to the first drugs to tame the chronic, painful gut disorder.

AMP encourage FDA to collect data of oversight models to implement new approaches